New clinical technologies in drug development;Neue klinische technologien in der arzneimittelentwicklung

Internist

Volumn 49, Issue 2, 2008, Pages 232-237

  Otte, A ^a   Rose C ^a   Zahringer A ^a   Maier Lenz, H ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Clinical studies; Clinical technologies implementation; Drug development; Functional imaging; Risk reduction

Indexed keywords

APREPITANT; ELETRIPTAN; IBRITUMOMAB TIUXETAN; LEVODOPA; NALTREXONE;

BIOTECHNOLOGY; CLINICAL STUDY; CLINICAL TECHNOLOGIES IMPLEMENTATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG COST; DRUG METABOLISM; DRUG MONITORING; DRUG TARGETING; FOLLOW UP; HUMAN; MEDICAL DECISION MAKING; NUCLEAR MEDICINE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; REVIEW; RISK REDUCTION;

CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; TECHNOLOGY, PHARMACEUTICAL;

EID: 39149132455     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-007-1988-5     Document Type: Review

References (18)

1. Catafau AM, Etcheberrigaray A, Perez de los Cobos J et al. (1999) Regional cerebral blood flow changes in chronic alcoholic patients induced by naltrexone challenge during detoxification. J Nucl Med 40: 19-24
2. Catafau AM, Martin JC, Pascual-Sedano B et al. (2000) Retard L-Dopa induces higher frontal activation than standard L-Dopa during cognitive performance in Parkinson's disease. J Nucl Med (Suppl) 41: 219-220
3. FDA (2004) Innovation - Stagnation. Challenge and opportunity on the critical path to new medical products.
4. Feld M, De Roo M (2003) History of nuclear medicine in Europe. Schattauer, Stuttgart
5. Frank R, Hargreaves R (2003) Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2: 566-580
6. Gordon LI, Witzig T, Molina A et al. (2004) Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 5: 98-101
7. Otte A (2007) Angewandte klinische Forschung II: Neue klinische Technologien in der Medikamentenentwicklung (Clinical Technologies Implementation). ISBN 978-386692-067-5. Wissenschaftliche Hochschule Lahr, Stuttgart
8. Otte A (2007) Arzneimitteltestung am Menschen: Die Risiken im Licht der Katastrophe von London. Internist 48: 636-641
9. Otte A, Herrmann R, Heppeler A et al. (1999) Yttrium-90-DOTATOC: first clinical results. Eur J Nucl Med 26: 1439-1447
10. Otte A, Herrmann R, Maecke HR, Müller-Brand J (1999) Yttrium-90-DOTATOC: Ein neues Somatostatinanalogon zur Krebstherapie von neuroendokrinen Tumoren. Yttrium-90-DOTATOC: a novel somatostatin analogue for the treatment of neuroendocrine carcinoma. Schweiz Rundsch Med Praxis 88: 1263-1268
11. 2O positron emission tomography (PET) study. Eur J Nucl Med Mol Imaging (Suppl 2) 30: S292
12. Otte A, Mueller-Brand J, Dellas S et al. (1998) Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 351: 417-418
13. Otte A, Thompson SL (2006) Practical and clinical benefits of radioimmunotherapy lead to advantages in cost-effectiveness in the treatment of patients with non-Hodgkin's lymphoma. Nucl Med Commun 27: 753-756
14. Wiseman GA, Gordon LI, Multani PS et al. (2002) Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99: 4336-4342
15. Witzig TE, Flinn IW, Gordon LI et al. (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20: 3262-3269
16. Witzig TE, Gordon LI, Cabanillas F et al. (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20: 2453-2463
17. Otte A, Audenaert K, Peremans K et al. (2004). Nuclear medicine in psychiatry. Springer, Berlin Heidelberg New York Tokyo
18. Otte A (2000) Das Halswirbelsäulen-Schleudertrauma: Neue Wege der funktionellen Bildgebung des Gehirns. Springer, Berlin Heidelberg New York Tokyo